Coherus BioSciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Coherus BioSciences, Inc. (the "Company") on September 14, 2015, reporting events that occurred on September 10, 2015. The filing details a material definitive agreement involving the sale of equity securities.
Key Financial Metrics
- Transaction Type: Private placement of common stock.
- Shares Sold: 390,167 shares.
- Price Per Share: $25.63 (equal to the closing trading price on September 9, 2015).
- Gross Proceeds: Approximately $10 million.
- Buyer: Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH (collectively "Baxalta").
- Registration Status: Exempt from registration under Section 4(a)(2) of the Securities Act and Regulation D.
Material Changes and Agreements
The Company entered into a Stock Purchase Agreement and a Registration Rights Agreement with Baxalta. Under the Registration Rights Agreement, the Company agreed to file a registration statement with the SEC no later than December 4, 2015, to register the resale of the shares. The Company committed to using reasonable best efforts to have the statement declared effective within 60 days of filing and agreed to indemnify selling holders and pay associated fees and expenses.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the securities are unregistered and may not be offered or sold in the United States absent registration or an applicable exemption.
Investor Verification Checklist
- Verify the final closing of the $10 million transaction and the actual number of shares issued.
- Confirm the filing date and effectiveness of the registration statement required by December 4, 2015.
- Review the full text of the Stock Purchase Agreement (Exhibit 10.1) for any additional covenants or conditions.
- Assess the impact of the dilution from 390,167 new shares on existing shareholders.